Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bauer

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological responseMattias Mandorfer, Fanny Turon, Sabela Lens, et al.
The Journal of Pathology|August 22, 2014
Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomasMiriam J Smith, Andrew J Wallace, Chris Bennett, et al.
Hepatology (Baltimore, Md.)|October 30, 2021
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologiesPhilipp Königshofer, Benedikt Silvester Hofer, Ksenia Brusilovskaya, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancersSalomon Tendler, Roberto De Gregorio, Paul Balderes, et al.
Journal of Medicinal Chemistry|February 21, 2015
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitorsEmily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.
Journal of Medicinal Chemistry|April 23, 2015
Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met InhibitorsEmily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.
Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological responseMattias Mandorfer, Fanny Turon, Sabela Lens, et al.
The Journal of Pathology|August 22, 2014
Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomasMiriam J Smith, Andrew J Wallace, Chris Bennett, et al.
Hepatology (Baltimore, Md.)|October 30, 2021
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologiesPhilipp Königshofer, Benedikt Silvester Hofer, Ksenia Brusilovskaya, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Scientific Reports|June 21, 2018
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic ratsPhilipp Schwabl, Ksenia Brusilovskaya, Paul Supper, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancersSalomon Tendler, Roberto De Gregorio, Paul Balderes, et al.
Journal of Medicinal Chemistry|February 21, 2015
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitorsEmily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.
Journal of Medicinal Chemistry|April 23, 2015
Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met InhibitorsEmily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.
Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsAlessandro A Boezio, Loren Berry, Brian K Albrecht, et al.
Pageof 18